|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Leishmaniasis | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Leishmaniasis, Cutaneous | |||||
| 3 | More general conditions related to this trial | ||||
| Mastigophora Infections | |||||
| Parasitic Diseases | |||||
| Protozoan Infections | |||||
| Sarcomastigophora Infections | |||||
| Skin Diseases | |||||
| Skin Diseases, Infectious | |||||
| Skin Diseases, Parasitic | |||||
| 4 | Interventions listed in this trial | ||||
| allopurinol | |||||
| glucantime | |||||
| 5 | Additional drug interventions recognized in this trial | ||||
| Meglumine antimoniate | |||||
| 6 | More general drug interventions related to this trial | ||||
| Anti-Infective Agents | |||||
| Antimetabolites | |||||
| Antioxidants | |||||
| Antiparasitic Agents | |||||
| Antiprotozoal Agents | |||||
| Antirheumatic Agents | |||||
| Enzyme Inhibitors | |||||
| Free Radical Scavengers | |||||
| Gout Suppressants | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| Protective Agents | |||||
| Therapeutic Uses | |||||
| 7 | Sponsors listed in this trial | ||||
| National Institute of Allergy and Infectious Diseases (NIAID) | |||||
| Harvard School of Public Health | |||||